Principal Financial Group Inc. Grows Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Principal Financial Group Inc. lifted its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 68.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 157,798 shares of the specialty pharmaceutical company's stock after purchasing an additional 64,021 shares during the quarter. Principal Financial Group Inc. owned about 0.72% of ANI Pharmaceuticals worth $10,565,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ANIP. Millennium Management LLC boosted its stake in ANI Pharmaceuticals by 89.3% in the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock worth $55,437,000 after purchasing an additional 473,097 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of ANI Pharmaceuticals by 4.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company's stock worth $37,906,000 after buying an additional 30,420 shares during the period. Deep Track Capital LP grew its holdings in shares of ANI Pharmaceuticals by 28.6% during the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock valued at $35,879,000 after buying an additional 144,214 shares during the last quarter. William Blair Investment Management LLC increased its position in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. William Blair Investment Management LLC now owns 485,268 shares of the specialty pharmaceutical company's stock valued at $26,826,000 after acquiring an additional 10,440 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of ANI Pharmaceuticals by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 428,999 shares of the specialty pharmaceutical company's stock valued at $23,720,000 after acquiring an additional 3,774 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ANIP. HC Wainwright initiated coverage on ANI Pharmaceuticals in a report on Thursday, July 10th. They issued a "buy" rating and a $84.00 price objective on the stock. Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research note on Monday, April 21st. Wall Street Zen cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, ANI Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $78.88.

ANI Pharmaceuticals Price Performance

NASDAQ ANIP traded up $1.46 during trading hours on Thursday, reaching $68.06. The company's stock had a trading volume of 21,251 shares, compared to its average volume of 317,191. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of -53.59 and a beta of 0.57. The company's 50-day moving average is $62.95 and its two-hundred day moving average is $62.48. The company has a debt-to-equity ratio of 1.46, a current ratio of 2.66 and a quick ratio of 1.98. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. The business had revenue of $197.12 million during the quarter, compared to the consensus estimate of $179.75 million. During the same period in the prior year, the company posted $0.82 EPS. The business's quarterly revenue was up 43.4% on a year-over-year basis. On average, equities analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, SVP Ori Gutwerg sold 881 shares of the business's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $60.07, for a total transaction of $52,921.67. Following the completion of the sale, the senior vice president owned 89,897 shares of the company's stock, valued at $5,400,112.79. The trade was a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Christopher Mutz sold 4,000 shares of the business's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total value of $241,800.00. Following the sale, the insider owned 107,317 shares of the company's stock, valued at approximately $6,487,312.65. This trade represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,681 shares of company stock valued at $345,222 over the last ninety days. Corporate insiders own 11.10% of the company's stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.